托珠单抗治疗巨细胞动脉炎相关大血管炎的PET/CT完全消退与主动脉扩张风险
回顾性多中心研究纳入91例托珠单抗治疗的巨细胞动脉炎相关大血管炎患者,69例(76%)达到临床缓解和PET/CT完全代谢应答。随访中,完全代谢消退者仅1例(1%)发生主动脉扩张,而未达到持续完全消退者4例(18%)发生(log-rank P=0.006)。提示托珠单抗或可降低后续主动脉扩张风险。
要点
- 托珠单抗治疗GCA相关LVV,76%患者达到PET/CT完全代谢应答。
- 完全代谢消退者主动脉扩张发生率1%,未持续消退者18%(P=0.006)。
- 停用托珠单抗后12个月内,14%患者出现LVV复发。
核心结论
- 托珠单抗是GCA相关LVV达到PET/CT完全代谢应答的有效选择,且可能降低后续主动脉扩张风险。
研究设计与样本
- 回顾性多中心研究,纳入91例PET/CT证实GCA相关LVV且接受托珠单抗并至少一次重复PET/CT的患者。
主要发现
- 91例中64例(70%)为女性,中位年龄69(54-83)岁。
- 69例(76%)达到临床缓解和PET/CT完全代谢应答。
- 完全代谢应答者中30例停用所有GCA治疗且阴性PET/CT后随访>12个月未复发,其余39例仍在治疗或阴性PET/CT后随访<12个月。
- 停用托珠单抗后12个月内,13例(14%)在第三次PET/CT出现LVV复发。
- 随访期间,完全代谢消退者1例(1%)发生主动脉扩张,未达到持续完全PET/CT消退者4例(18%)发生(log-rank检验P=0.006)。
关键数值与推荐
- PET/CT完全代谢应答定义为视觉血管与肝脏FDG摄取分级量表0级或1级。
临床怎么用
- 对托珠单抗治疗的GCA相关LVV患者,重复PET/CT评估完全代谢应答有助于识别主动脉扩张低风险者。
局限性
- 回顾性设计,样本量有限,随访时间不一,部分患者阴性PET/CT后随访不足12个月。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The proportion of patients with giant cell arteritis (GCA)-related large vessel vasculitis (LVV) treated with tocilizumab (TCZ) who achieve a complete metabolic response on repeated 18 F-fluorodeoxyglucose positron emission tomography (18FDG-PET)-CT (PET/CT) is unknown. METHODS: We conducted a retrospective multicentre study that enrolled patients with GCA-related LVV demonstrated on PET/CT, who were treated with TCZ and underwent at least one repeated PET/CT. The primary endpoint was the proportion of patients with vascular extinction on repeated PET/CT during or after TCZ treatment (grade 0 or 1 on the visual vascular to liver FDG uptake grading scale). RESULTS: A total of 91 patients (64 women (70%), median age: 69 (54-83) years) were included. Clinical remission and a complete metabolic response on PET/CT were observed in 69 patients (76%). Among these, 30 had discontinued all GCA treatments and had not relapsed after >12 months of follow-up post negative PET/CT; the remaining 39 patients were still treated or had <12 months of follow-up after the negative PET/CT.13 (14%) patients experienced a relapse of LVV on a third PET/CT within 12 months after TCZ discontinuation. During follow-up, an aortic dilation occurred in one (1%) patient with complete metabolic extinction and in four (18%) patients who did not show complete and persisting PET/CT extinction (p=0.006 by log-rank test). CONCLUSION: This study suggests that TCZ is an interesting therapeutic option for achieving complete metabolic response on PET/CT in patients with GCA-related LVV. The subsequent risk of aortic dilation may be reduced.
引用
- Dumont A, Espitia O, Samson M, et al. Complete PET/CT extinction and subsequent risk of aortic dilation in patients with giant cell arteritis-related large vessel vasculitis treated with tocilizumab. RMD Open. 2026. PMID: 41895800. doi:10.1136/rmdopen-2025-006563
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。